Company Analysis

Inovio Pharmaceuticals, Inc. (INO)

Nasdaq: INO · Pharmaceutical Preparations · Plymouth Meeting, PA · filing with the SEC since 1999
Grade3.5
◀ Past 3.2● Present 3.3▶ Future 3.9
1 est.

Who runs Inovio Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Shea Jacqueline Elizabeth
Chief Executive Officer. First filing Mar 2019, latest May 21, 2026, 5 filings in all.
Officers reporting now
4
of 11 people with a filing in the last fifteen months
Directors reporting now
7
20 people on the record since 2006
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Shea Jacqueline ElizabethChief Executive OfficerMar 2019May 21, 2026none
Kies PeterCFOMar 2006May 21, 2026none
Humeau LaurentChief Scientific OfficerMar 2019May 21, 2026none
Sumner Michael JohnChief Medical OfficerJul 2022May 21, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Benito Simon XdirectorJun 2006May 21, 2026none
Dansey Roger DdirectorMay 2021May 21, 2026none
Miller Ann CalbydirectorMar 2019May 21, 2026none
Shepard JaydirectorJan 2020May 21, 2026none
Weiner David B.directorMar 2016May 21, 2026none
Yarno Wendy LdirectorDec 2017May 21, 2026none
Zoth Lota S.directorJan 2019May 21, 2026none
Earlier names on the record9, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton INO · research, not advice